SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Directorate Change

23 Mar 2015 07:00

RNS Number : 0783I
Victrex PLC
23 March 2015
 
 

 

 

 

 

 

23 March 2015

 

Victrex plc - Directorate change

 

Victrex appoints Martin Court to the Board

 

The Board of Victrex plc, an innovative world leader in high performance polymer solutions, is pleased to announce the appointment of Dr Martin Court as an Executive Director, effective from 1 April 2015.

 

Martin, who joined Victrex in February 2013, is Managing Director of Invibio, Victrex's medical business. Invibio focuses on solutions for the spinal fusion market, as well as developing solutions for the dental, trauma and knee markets. His appointment further strengthens the Board, with Victrex's other divisional managing director, Tim Cooper, Managing Director of Victrex Polymer Solutions, already an Executive Director.

 

Martin, aged 53, has a wealth of proven international experience in the medical and high performance polymer industry, including with Cytec Industries, and in a number of senior roles at both ICI and UCB. He is an INSEAD alumni, holds a doctorate in the field of surface chemistry and fracture mechanics and a BSc (Eng) degree in mineral technology from Imperial College of Science and Technology.

Larry Pentz, Chairman of Victrex, said: "I am delighted to welcome Martin to the Board. His appointment reflects not only a natural progression, in having both of our divisional heads on the Board, but that an important part of our future portfolio will be in high value medical markets."

David Hummel, Chief Executive of Victrex, said: "Martin has helped refine our focus on the high value growth platforms that will further develop the market for PEEK in the future, in line with our strategy and as the market leader. I look forward to Martin joining the Board and his continued contribution to Victrex."

 

About Victrex:

 

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

Notes:

Upon his appointment to the Board, Martin will receive a basic salary of £257,000. He will also be eligible to participate in the Company's short and long term executive incentive programmes, as outlined in Victrex's Annual Report.

Enquiries:

Victrex plc:

 

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

 

Pendomer Communications:

Charlie Armitstead +44 (0) 203 603 5220

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEALDEADNSEFF
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.